A network of more than 360 Indian cancer centres, run from Tata Memorial, that agrees common treatment guidelines, buys cancer drugs together at a fraction of list price and runs shared tumour boards and trials.
The National Cancer Grid was set up by the Tata Memorial Centre with support from the Department of Atomic Energy to give every Indian patient the same standard of care wherever they are treated. Its secretariat sits at Tata Memorial Hospital, Mumbai, and its membership has grown to a network of more than 360 cancer centres, research institutes, patient groups and charities across India.
The Grid publishes resource-stratified NCG guidelines, runs virtual tumour boards, an e-learning portal and quality programmes (EQAS and EQUIP), trains oncologists in research methods through the CReDO workshops (more than 250 trained since 2015) and issued India's Choosing Wisely list of low-value practices. Its pooled procurement pilot pooled demand for 40 anticancer drugs from 23 centres worth about 15.6 billion rupees at maximum retail price and cut the bill by about 13.2 billion rupees, with savings of 23% to 99% per drug (median 82%). A national electronic medical record initiative for cancer centres followed in 2025. The NCG is the practical backbone of Indian cancer care and the reason low-cost trial results from Mumbai spread quickly across the country.
The surgeon who built the National Cancer Grid into a network of hundreds of Indian cancer centres and used its buying power to cut cancer drug prices by a median of 82%.
Sudeep Gupta leads India's largest cancer centre and its programme of pragmatic, affordable trials.
A surgeon-scientist whose low-cost randomised trials, from peritumoral lidocaine to timing of surgery, challenged assumptions in breast cancer.
One institution page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Buying power, not new science, is the fastest lever on cancer drug prices in a decentralised, under-funded system. The Grid's model is being extended across its 360-plus centres and offers a template for other middle-income countries and for pooled buying of newer, patented drugs.
One institution page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One institution page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares Tata Medical Center, Kolkata, Tata Memorial Centre, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Fragmented care and guideline gaps.
Shares Rajendra Badwe, Sudeep Gupta, Tata Memorial Centre, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation.
Shares Kidwai Memorial Institute of Oncology, Cancer Institute (WIA), Adyar, Cancer registries and population surveillance, Data silos.
Shares Tata Medical Center, Kolkata, Tata Memorial Centre, Fragmented care and guideline gaps, Most of the world has almost no cancer care.
Shares Sudeep Gupta, Tata Memorial Centre, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Most of the world has almost no cancer care.
Shares Cancer Institute (WIA), Adyar, Cancer registries and population surveillance, Global oncology and access in low- and middle-income countries.
Shares Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Tata Memorial Centre, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Most of the world has almost no cancer care.